Bismuth Subsalicylate

Curling Ulcer, Indigestion, Flatulence + 9 more

Treatment

16 FDA approvals

20 Active Studies for Bismuth Subsalicylate

What is Bismuth Subsalicylate

Bismuth subsalicylate

The Generic name of this drug

Treatment Summary

Bismuth subsalicylate is a medication used to relieve nausea, diarrhea, and stomach discomfort. It is an antacid and anti-diarrheal agent that has been around for over 100 years and was approved by the FDA in 1939. It is an active ingredient in Pepto-Bismol, an over-the-counter medication, and is also a key component of HELIDAC Therapy, a treatment regimen used to treat patients with an infection of the bacteria H. pylori.

Topcare stomach relief original strength

is the brand name

image of different drug pills on a surface

Bismuth Subsalicylate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Topcare stomach relief original strength

Bismuth subsalicylate

1989

4

Approved as Treatment by the FDA

Bismuth subsalicylate, also called Topcare stomach relief original strength, is approved by the FDA for 16 uses such as Curling Ulcer and Heartburn .

Curling Ulcer

Used to treat Duodenal Ulcer in combination with Metronidazole

Heartburn

Used to treat Heartburn in combination with Calcium carbonate

Upset stomach

Traveler's Diarrhea

Indigestion

Helicobacter Pylori Infection

Used to treat Helicobacter Pylori Infection in combination with Metronidazole

Gastroenteritis

Flatulence

Duodenal Ulcer

Used to treat Duodenal Ulcer in combination with Metronidazole

Heartburn

Used to treat Heartburn in combination with Calcium carbonate

Diarrhea

belching

Flatulence

gastrointestinal fullness

Diarrhea

Gastrointestinal distress

Effectiveness

How Bismuth Subsalicylate Affects Patients

Bismuth subsalicylate is a drug with multiple benefits, such as reducing flatulence and diarrhea, relieving gastrointestinal discomfort, and preventing traveler's diarrhea. It also has antimicrobial properties, which can help to fight certain bacteria, including the bacteria that causes stomach ulcers (_Helicobacter pylori_) and other enteric pathogens like _Clostridium difficile_ and _Salmonella_. Bismuth subsalicylate can be used together with other drugs to help treat stomach ulcers.

How Bismuth Subsalicylate works in the body

Bismuth subsalicylate works by breaking down into two substances, salicylic acid and bismuth, in the stomach. The bismuth then binds to other molecules in the stomach to create bismuth salts, which have antimicrobial properties that stop bacteria from sticking to and growing on the stomach's mucosal cells. The salicylic acid acts as an anti-inflammatory, preventing the formation of pro-inflammatory molecules. Bismuth subsalicylate also helps protect the stomach from further damage, and prevents bacteria from performing certain activities like making enzymes. Altogether, these properties help heal ulcers in

When to interrupt dosage

The quantity of Bismuth Subsalicylate is reliant upon the identified disorder, like Nausea, Flatulence and Diarrhea. The amount of dosage is contingent upon the technique of delivery indicated in the table beneath.

Condition

Dosage

Administration

Gastrointestinal distress

, 52.5 mg/mL, 26.2 mg/mL, 105.0 mg/mL, 262.0 mg, 17.47 mg/mL, 35.0 mg/mL, 2.62 mg/mg, 525.0 mg, 17.5 mg/mL, 300.0 mg, 1.7 %, 524.0 mg, 52.5 mg, 262.4 mg, 17.66 mg/mL, 17.6 mg/mL, 35.2 mg/mL, 23.6 mg/mL, 0.262 mg/mg

Oral, Suspension, Suspension - Oral, , Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, Powder - Oral, Kit, Tablet, film coated - Oral, Tablet, film coated, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Syrup, Syrup - Oral, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated - Oral; Topical, Oral; Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated

Gastroenteritis

, 52.5 mg/mL, 26.2 mg/mL, 105.0 mg/mL, 262.0 mg, 17.47 mg/mL, 35.0 mg/mL, 2.62 mg/mg, 525.0 mg, 17.5 mg/mL, 300.0 mg, 1.7 %, 524.0 mg, 52.5 mg, 262.4 mg, 17.66 mg/mL, 17.6 mg/mL, 35.2 mg/mL, 23.6 mg/mL, 0.262 mg/mg

Oral, Suspension, Suspension - Oral, , Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, Powder - Oral, Kit, Tablet, film coated - Oral, Tablet, film coated, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Syrup, Syrup - Oral, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated - Oral; Topical, Oral; Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated

Diarrhea

, 52.5 mg/mL, 26.2 mg/mL, 105.0 mg/mL, 262.0 mg, 17.47 mg/mL, 35.0 mg/mL, 2.62 mg/mg, 525.0 mg, 17.5 mg/mL, 300.0 mg, 1.7 %, 524.0 mg, 52.5 mg, 262.4 mg, 17.66 mg/mL, 17.6 mg/mL, 35.2 mg/mL, 23.6 mg/mL, 0.262 mg/mg

Oral, Suspension, Suspension - Oral, , Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, Powder - Oral, Kit, Tablet, film coated - Oral, Tablet, film coated, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Syrup, Syrup - Oral, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated - Oral; Topical, Oral; Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated

Diarrhea

, 52.5 mg/mL, 26.2 mg/mL, 105.0 mg/mL, 262.0 mg, 17.47 mg/mL, 35.0 mg/mL, 2.62 mg/mg, 525.0 mg, 17.5 mg/mL, 300.0 mg, 1.7 %, 524.0 mg, 52.5 mg, 262.4 mg, 17.66 mg/mL, 17.6 mg/mL, 35.2 mg/mL, 23.6 mg/mL, 0.262 mg/mg

Oral, Suspension, Suspension - Oral, , Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, Powder - Oral, Kit, Tablet, film coated - Oral, Tablet, film coated, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Syrup, Syrup - Oral, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated - Oral; Topical, Oral; Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated

gastrointestinal fullness

, 52.5 mg/mL, 26.2 mg/mL, 105.0 mg/mL, 262.0 mg, 17.47 mg/mL, 35.0 mg/mL, 2.62 mg/mg, 525.0 mg, 17.5 mg/mL, 300.0 mg, 1.7 %, 524.0 mg, 52.5 mg, 262.4 mg, 17.66 mg/mL, 17.6 mg/mL, 35.2 mg/mL, 23.6 mg/mL, 0.262 mg/mg

Oral, Suspension, Suspension - Oral, , Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, Powder - Oral, Kit, Tablet, film coated - Oral, Tablet, film coated, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Syrup, Syrup - Oral, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated - Oral; Topical, Oral; Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated

belching

, 52.5 mg/mL, 26.2 mg/mL, 105.0 mg/mL, 262.0 mg, 17.47 mg/mL, 35.0 mg/mL, 2.62 mg/mg, 525.0 mg, 17.5 mg/mL, 300.0 mg, 1.7 %, 524.0 mg, 52.5 mg, 262.4 mg, 17.66 mg/mL, 17.6 mg/mL, 35.2 mg/mL, 23.6 mg/mL, 0.262 mg/mg

Oral, Suspension, Suspension - Oral, , Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, Powder - Oral, Kit, Tablet, film coated - Oral, Tablet, film coated, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Syrup, Syrup - Oral, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated - Oral; Topical, Oral; Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated

Curling Ulcer

, 52.5 mg/mL, 26.2 mg/mL, 105.0 mg/mL, 262.0 mg, 17.47 mg/mL, 35.0 mg/mL, 2.62 mg/mg, 525.0 mg, 17.5 mg/mL, 300.0 mg, 1.7 %, 524.0 mg, 52.5 mg, 262.4 mg, 17.66 mg/mL, 17.6 mg/mL, 35.2 mg/mL, 23.6 mg/mL, 0.262 mg/mg

Oral, Suspension, Suspension - Oral, , Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, Powder - Oral, Kit, Tablet, film coated - Oral, Tablet, film coated, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Syrup, Syrup - Oral, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated - Oral; Topical, Oral; Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated

Indigestion

, 52.5 mg/mL, 26.2 mg/mL, 105.0 mg/mL, 262.0 mg, 17.47 mg/mL, 35.0 mg/mL, 2.62 mg/mg, 525.0 mg, 17.5 mg/mL, 300.0 mg, 1.7 %, 524.0 mg, 52.5 mg, 262.4 mg, 17.66 mg/mL, 17.6 mg/mL, 35.2 mg/mL, 23.6 mg/mL, 0.262 mg/mg

Oral, Suspension, Suspension - Oral, , Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, Powder - Oral, Kit, Tablet, film coated - Oral, Tablet, film coated, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Syrup, Syrup - Oral, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated - Oral; Topical, Oral; Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated

Upset stomach

, 52.5 mg/mL, 26.2 mg/mL, 105.0 mg/mL, 262.0 mg, 17.47 mg/mL, 35.0 mg/mL, 2.62 mg/mg, 525.0 mg, 17.5 mg/mL, 300.0 mg, 1.7 %, 524.0 mg, 52.5 mg, 262.4 mg, 17.66 mg/mL, 17.6 mg/mL, 35.2 mg/mL, 23.6 mg/mL, 0.262 mg/mg

Oral, Suspension, Suspension - Oral, , Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, Powder - Oral, Kit, Tablet, film coated - Oral, Tablet, film coated, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Syrup, Syrup - Oral, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated - Oral; Topical, Oral; Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated

Flatulence

, 52.5 mg/mL, 26.2 mg/mL, 105.0 mg/mL, 262.0 mg, 17.47 mg/mL, 35.0 mg/mL, 2.62 mg/mg, 525.0 mg, 17.5 mg/mL, 300.0 mg, 1.7 %, 524.0 mg, 52.5 mg, 262.4 mg, 17.66 mg/mL, 17.6 mg/mL, 35.2 mg/mL, 23.6 mg/mL, 0.262 mg/mg

Oral, Suspension, Suspension - Oral, , Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, Powder - Oral, Kit, Tablet, film coated - Oral, Tablet, film coated, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Syrup, Syrup - Oral, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated - Oral; Topical, Oral; Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated

Helicobacter Pylori Infection

, 52.5 mg/mL, 26.2 mg/mL, 105.0 mg/mL, 262.0 mg, 17.47 mg/mL, 35.0 mg/mL, 2.62 mg/mg, 525.0 mg, 17.5 mg/mL, 300.0 mg, 1.7 %, 524.0 mg, 52.5 mg, 262.4 mg, 17.66 mg/mL, 17.6 mg/mL, 35.2 mg/mL, 23.6 mg/mL, 0.262 mg/mg

Oral, Suspension, Suspension - Oral, , Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, Powder - Oral, Kit, Tablet, film coated - Oral, Tablet, film coated, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Syrup, Syrup - Oral, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated - Oral; Topical, Oral; Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated

Heartburn

, 52.5 mg/mL, 26.2 mg/mL, 105.0 mg/mL, 262.0 mg, 17.47 mg/mL, 35.0 mg/mL, 2.62 mg/mg, 525.0 mg, 17.5 mg/mL, 300.0 mg, 1.7 %, 524.0 mg, 52.5 mg, 262.4 mg, 17.66 mg/mL, 17.6 mg/mL, 35.2 mg/mL, 23.6 mg/mL, 0.262 mg/mg

Oral, Suspension, Suspension - Oral, , Liquid, Liquid - Oral, Tablet, Tablet - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, Powder - Oral, Kit, Tablet, film coated - Oral, Tablet, film coated, Kit - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Capsule, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Syrup, Syrup - Oral, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated - Oral; Topical, Oral; Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated

Warnings

Bismuth Subsalicylate Contraindications

Condition

Risk Level

Notes

Stomach Ulcer

Do Not Combine

Blood in Stool

Do Not Combine

Pulse Frequency

Do Not Combine

Melena

Do Not Combine

Fever

Do Not Combine

Gastrointestinal Hemorrhage

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Bismuth Subsalicylate may interact with Pulse Frequency

There are 20 known major drug interactions with Bismuth Subsalicylate.

Common Bismuth Subsalicylate Drug Interactions

Drug Name

Risk Level

Description

Bismuth subcarbonate

Major

Bismuth subsalicylate may increase the neurotoxic activities of Bismuth subcarbonate.

Bismuth subcitrate potassium

Major

Bismuth subsalicylate may increase the neurotoxic activities of Bismuth subcitrate potassium.

Bismuth subgallate

Major

Bismuth subsalicylate may increase the neurotoxic activities of Bismuth subgallate.

Bismuth subnitrate

Major

Bismuth subsalicylate may increase the neurotoxic activities of Bismuth subnitrate.

Probenecid

Major

The therapeutic efficacy of Probenecid can be decreased when used in combination with Bismuth subsalicylate.

Bismuth Subsalicylate Toxicity & Overdose Risk

The lowest toxic dose of bismuth subsalicylate in humans is 700mg/kg. In rats, the toxic dose is 1200mg/kg when taken orally, 542mg/kg when given via intraperitoneal route, and 980mg/kg when given subcutaneously. Taking too much bismuth subsalicylate over a long period of time can cause blackened tongue and teeth, fatigue, changes in mood, mental deterioration, and nerve damage. Other symptoms can include difficulty thinking, shaking, feeling tired, difficulty sleeping, confusion, twitching, seizures, depression, anxiety, and low mood

image of a doctor in a lab doing drug, clinical research

Bismuth Subsalicylate Novel Uses: Which Conditions Have a Clinical Trial Featuring Bismuth Subsalicylate?

68 active research projects are investigating the potential of Bismuth Subsalicylate to regulate Flatulence, Gastrointestinal Fullness and Curling Ulcer.

Condition

Clinical Trials

Trial Phases

Gastroenteritis

12 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Early Phase 1

Curling Ulcer

0 Actively Recruiting

Diarrhea

0 Actively Recruiting

Diarrhea

0 Actively Recruiting

gastrointestinal fullness

0 Actively Recruiting

Indigestion

6 Actively Recruiting

Phase 3, Not Applicable, Phase 2

Helicobacter Pylori Infection

2 Actively Recruiting

Not Applicable, Phase 4

Flatulence

0 Actively Recruiting

Heartburn

2 Actively Recruiting

Phase 3, Not Applicable

Upset stomach

0 Actively Recruiting

belching

0 Actively Recruiting

Gastrointestinal distress

9 Actively Recruiting

Phase 2, Early Phase 1, Phase 1, Phase 3, Not Applicable, Phase 4

Bismuth Subsalicylate Reviews: What are patients saying about Bismuth Subsalicylate?

5

Patient Review

5/25/2012

Bismuth Subsalicylate for Indigestion

I had gastric bypass surgery six years ago and I still have trouble digesting my food. This medication has helped me be able to eat, but now my tongue is black. I'm not comfortable with this because it's not a temporary side effect; I have to take the medication every time I eat. I don't want to walk around with a black tongue for the rest of my life.

5

Patient Review

10/14/2013

Bismuth Subsalicylate for Diarrhea

After trying reglan and diociline without success, I decided to just take this medication myself. The results were almost instantaneous and very impressive.

5

Patient Review

4/18/2009

Bismuth Subsalicylate for Diarrhea

4.7

Patient Review

5/11/2016

Bismuth Subsalicylate for Diarrhea

My doctor recommended this for my colitis-related diarrhea, and it's been working great! I take it three times a day when I'm having issues, and it's really helped. Of course, I still have to be careful about what I eat, but this has made a big difference.

2.7

Patient Review

9/8/2010

Bismuth Subsalicylate for Indigestion

Pepto-Bismol has been a game changer for me. I take two pills in the morning and two in the evening, as per my doctor's orders, and I haven't felt this good in over 20 years.

2

Patient Review

10/29/2014

Bismuth Subsalicylate for Diarrhea

Unfortunately, my condition worsened after taking this treatment.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about bismuth subsalicylate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who should not take bismuth subsalicylate?

"This product is not recommended for children or teens under the age of 18 who have chickenpox, the flu, or any undiagnosed illness, or who have recently received a vaccine. Taking aspirin or aspirin-like products in these cases increases the risk of developing Reye's syndrome, a rare but serious illness."

Answered by AI

Is bismuth subsalicylate the same as Pepto-Bismol?

"The brand name for bismuth subsalicylate is Pepto-Bismol. Bismuth has antimicrobial effects against certain bacteria that cause diarrhea, while subsalicylate has antisecretory effects against fluid and electrolyte loss. Bismuth subsalicylate also has anti-inflammatory actions on the stomach and intestinal lining."

Answered by AI

When should you take bismuth subsalicylate?

"For diarrhea or upset stomach:

Adults and teenagers should take 2 tablets every half hour to one hour. You should not take more than 16 tablets in twenty-four hours. Children should not use this medication."

Answered by AI

Does bismuth subsalicylate have side effects?

"Side effects of bismuth subsalicylate can include changes in behaviour, nausea and vomiting, hearing loss or ringing in the ears, diarrhoea lasting longer than 2 days, or worsening of stomach symptoms."

Answered by AI

Clinical Trials for Bismuth Subsalicylate

Image of Stanford Digestive Health Clinic in Redwood City, United States.

MITI-001 for Irritable Bowel Syndrome

18 - 65
All Sexes
Redwood City, CA

While the pathophysiology of diarrhea-predominant irritable bowel syndrome (IBS-D) is complex and heterogeneous, dysbiosis of the gut microbiome is frequently observed, suggesting that a substantial subset of patients with irritable bowel syndrome (IBS) have symptoms that are initiated and/or perpetuated by a microbiome dysfunction. Successful randomized controlled trials (RCT) for IBS-D (Ford 2018; Black 2022) leveraging microbiome-targeted therapies (antibiotics or low microbiome fermentation diets) suggest the gut microbiome is at least partially involved in IBS symptoms. Furthermore, fecal microbiota transplantation (FMT) for patients with IBS-D has demonstrated promising results (El-Salhy 2020), supporting the possibility that altering the microbiome composition could ameliorate IBS-D symptoms. MITI-001 is a transplantable gut bacterial community composed of 157 live bacterial strains, encompassing 79 genera of commensal bacteria, that have been isolated from healthy donor stool, purified, and banked. The hypothesis of the proposed research is that MITI-001 can target the pathophysiologic lesion in a subset of IBS-D patients, restore the altered microbial metabolic process, and thus alleviate IBS-D symptoms.

Phase < 1
Waitlist Available

Stanford Digestive Health Clinic (+1 Sites)

Sean P Spencer, MD, PhD

Have you considered Bismuth Subsalicylate clinical trials?

We made a collection of clinical trials featuring Bismuth Subsalicylate, we think they might fit your search criteria.
Go to Trials
Image of Mayo Clinic in Rochester in Rochester, United States.

High Resolution Gastric Mapping and Gastroduodenal Manometry for Indigestion

18 - 80
All Sexes
Rochester, MN

Dyspepsia is a common problem attributed to gastric sensorimotor dysfunctions ie, delayed, or less frequently rapid gastric emptying (GE), impaired gastric accommodation, and increased gastric sensation. Therapeutic options manage symptoms, and there is no FDA approved medical therapy for dyspepsia. There is a need for better objective understanding of sensorimotor dysfunction in dyspepsia, as well as noninvasive, efficacious, safe, and inexpensive treatments for dyspepsia. The purpose of this research is to identify disturbances and characterize phenotypes in patients with functional dyspepsia, and to assess the correlations between symptoms (during the manometry and in daily life), gastric emptying, electrical activity (BSGM), and pressure activity (manometry).

Recruiting
Has No Placebo

Mayo Clinic in Rochester

Nicholas R Oblizajek, MD

Image of Montefiore Medical Center in Bronx, United States.

Fosaprepitant vs Metoclopramide for Nausea and Vomiting

18+
All Sexes
Bronx, NY

The study team proposes a double-blind, comparative effectiveness, randomized controlled trial (RCT) to address the following goal: to determine the relative efficacy and adverse event profile of fosaprepitant compared to the standard of care antiemetic metoclopramide. Fosaprepitant and its active metabolite aprepitant are a relatively new class of antiemetic that exclusively acts in the central nervous system by blocking neurokinin (NK-1) which is a key signaling molecule in the centrally mediated aspects of the vomiting reflex. Currently, fosaprepitant and aprepitant both have only two United Stated Food and Drug Administration (USFDA) approved indications for nausea and vomiting: chemotherapy-induced and postoperative. Neurokinin inhibitors are highly effective and generally well-tolerated. Therefore, this class of medication may be a more appropriate medication for the millions of patients with nausea and vomiting that seek care in emergency departments (EDs). Intravenous fosaprepitant is converted to the active metabolite aprepitant on the order of minutes and is significantly cheaper to procure at this time.

Phase 4
Waitlist Available

Montefiore Medical Center (+1 Sites)

Benjamin Friedman, MD

Have you considered Bismuth Subsalicylate clinical trials?

We made a collection of clinical trials featuring Bismuth Subsalicylate, we think they might fit your search criteria.
Go to Trials
Image of Brigham and Women's Hospital in Boston, United States.

Argon Plasma for Helicobacter Pylori Infection

18+
All Sexes
Boston, MA

The objective of the study is to investigate the efficacy and safety of an argon plasma-based therapy - HEAPE - in treating H. pylori infections during endoscopic procedures. By filling the stomach with sodium chloride solution that is treated with APC (PAL), the Investigators hypothesize a significant reduction in H. pylori. The use of PAL instead of direct application of APC allows for a broader and more homogeneous application throughout the stomach and a faster procedure time, as the fluid bypasses the thermal effects typically associated with higher electrical power settings and focuses on the bactericidal action of PAL. It is a procedure that does not involve thermal ablation of the stomach lining. Thus, side effects should be expected to be as low as possible. Two different PAL generation modalities will be compared in this study: 1. HEAPE direct: This modality is the direct generation of PAL in the stomach. The stomach is filled with sodium chloride solution which is then treated with APC. With HEAPE direct a potential decrease of reactive species is avoided, as the treatment happens directly at the intended location in the H. pylori infected stomach. 2. Pre-HEAPE: This modality features the treatment of sodium chloride with APC outside of the patient in a sterile container. After the APC treatment, the generated PAL is administered into the stomach with a syringe through the working channel of the endoscope. Pre-HEAPE allows an easier handling of the APC probe as the treatment of the sodium chloride solution can be done without an endoscope. To evaluate the immediate effect of this novel treatment approach the metabolic activity of H. pylori will be assessed using a urea breath test (UBT) before and after treatment. A reduction in H. pylori levels can be detected by a reduction in urease activity in the breath test. After the HEAPE procedure, patients are treated with antibiotics (best practice) as they would be under normal circumstances. Four weeks after treatment, another UBT is performed to determine if H. pylori has been eradicated or if additional antibiotic treatment is indicated. This two-arm, randomized, pilot, single-center, prospective clinical study is designed to evaluate the safety, tolerability and proof of concept that PAL has the ability to eradicate or reduce the bacterial load of H. pylori in humans.

Recruiting
Has No Placebo

Brigham and Women's Hospital

Christopher C Thompson, MD

Erbe Elektromedizin GmbH

Image of Montefiore Medical Center (Montefiore and Weiler EDs) in Bronx, United States.

Fosaprepitant for Nausea and Vomiting

18+
All Sexes
Bronx, NY

The study team proposes a randomized, double-blind, RCT to address the following goal: to determine the relative efficacy and adverse event profile of fosaprepitant compared to the standard of care antiemetic ondansetron. Fosaprepitant and its active metabolite aprepitant are a relatively new class of antiemetic that exclusively acts in the central nervous system by blocking neurokinin (NK-1) which is a key signaling molecule in the centrally mediated aspects of the vomiting reflex. Currently, fosaprepitant and aprepitant both have only two United Stated Food and Drug Administration (USFDA) approved indications for nausea and vomiting: chemotherapy-induced and postoperative. Neurokinin inhibitors are highly effective and generally well-tolerated. Therefore, this class of medication may be a more appropriate medication for the millions of patients with nausea and vomiting that seek care in EDs. Intravenous fosaprepitant is converted to the active metabolite aprepitant on the order of minutes and is significantly cheaper to procure at this time. The outcome for the efficacy analysis will be no need for additional medication to treat nausea and vomiting within 2 hours of investigational medication administration. The primary outcome for the tolerability analysis will be the development of any new symptom within 2 hours of medication administration.

Phase 2 & 3
Recruiting

Montefiore Medical Center (Montefiore and Weiler EDs) (+1 Sites)

Benjamin W Friedman, MD MS

Have you considered Bismuth Subsalicylate clinical trials?

We made a collection of clinical trials featuring Bismuth Subsalicylate, we think they might fit your search criteria.
Go to Trials